The FTC has secured what it says is the largest civil penalty ever obtained for a Hart-Scott-Rodino filing failure: a combined $12 million settlement with Edwards Lifesciences and Genesis MedTech over the acquisition of JC Medical. According to the agency, the companies structured the transaction to avoid premerger notification and waiting-period requirements under the HSR Act, prompting an enforcement action filed in the U.S. District Court for the District of Columbia by the DOJ on the FTC’s behalf.

That headline number matters. HSR enforcement has often been discussed in terms of “gun-jumping” or technical filing missteps, but this case signals continued agency willingness to treat deal structuring itself as a substantive compliance risk when regulators believe parties engineered a transaction to stay below reporting thresholds or otherwise evade review. For transactional counsel, the message is straightforward: the FTC is not limiting scrutiny to whether a form was filed, but also to whether the pathway to closing was designed to defeat the statute’s purpose.

The medical-device context adds another layer. Healthcare and device transactions already draw close antitrust attention because of concentrated markets, product pipeline overlap, and innovation concerns. Even where the underlying acquisition does not result in a litigated merger challenge, the agencies may still pursue a stand-alone HSR penalty case if they conclude the parties failed to comply with premerger reporting rules.

For in-house legal teams and compliance personnel, the case is a reminder that HSR analysis must begin early and extend beyond headline purchase price. Counsel should examine governance rights, staged investments, option arrangements, rollover equity, side agreements, and any other structural features that could affect reportability. Internal deal documents also matter: emails, board materials, and banker presentations can become central evidence if regulators later argue that a structure was chosen to avoid a filing obligation.

Litigators should also take note of the forum and posture. The government brought the matter in federal court in Washington, D.C., reinforcing that HSR enforcement remains an active civil-penalty tool even outside blockbuster merger litigation. That creates practical downstream risk for companies facing shareholder scrutiny, follow-on investigations, or board-level questions about controls around M&A compliance.

More broadly, this settlement fits a continuing pattern in antitrust enforcement: agencies are pressing procedural statutes aggressively, not just substantive competition claims. For legal professionals advising on acquisitions, especially in regulated or highly concentrated industries, the cost of getting HSR wrong may now be measured not only in delay and second-request burden, but in record-setting penalties.